KD

Kindstar Globalgene Technology IncOOTC KDGTF Stock Report

Last reporting period 30 Jun, 2024

Updated —

Last price

Market cap $B

0.159

Micro

Exchange

OOTC - OTC

KDGTF Stock Analysis

KD

Uncovered

Kindstar Globalgene Technology Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

0/100

Low score

Market cap $B

0.159

Dividend yield

1.77 %

Shares outstanding

981.08 B

Kindstar Globalgene Technology, Inc. is an investment holding company, which engages in the provision of clinical testing services. The company is headquartered in Wuhan, Hubei and currently employs 3,052 full-time employees. The company went IPO on 2021-07-16. The firm operates nine segments. Hematology Testing segment includes testing services related to blood diseases. Genetic Diseases and Rare Diseases segment includes testing services from the rare disease. Infectious Diseases segment includes testing services from the infection department. Oncology segment includes testing related to oncology diseases. Neurology segment includes testing services related to neurological diseases undertaken by the Group. Maternity-related Diseases segment includes testing services related to maternity. COVID-19 Related Testing segment includes testing services related to COVID-19. Routine Testing segment conducts routine tests for the doctors’ daily diagnoses. The Others segment includes testing services for research and development (R&D) projects and others and miscellaneous services.

View Section: Eyestock Rating